ACR open rheumatology最新文献

{"title":"Sex-Associated Disparities in Industry Payments to US Authors in High-Impact Rheumatology Journals: Correlation with Author Impact.","authors":"William Stohl, Krishan Parikh, Anuj Parikh, Sheldon M Stohl","doi":"10.1002/acr2.70078","DOIUrl":"10.1002/acr2.70078","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to assess sex-associated disparities in the frequency and magnitude of industry payments to US physician authors in high-impact rheumatology journals and their correlation with author impact.</p><p><strong>Methods: </strong>US authors of publications in four high-impact rheumatology journals were vetted on Open Payments Database (OPD) for industry payments. The h-index (an accepted metric of author impact), physician type, and dollar amounts for each OPD category were recorded. Differences in the percentages of male versus female US authors with or without OPD entries, differences in research-associated and non-research-associated payments, and differences in h-indexes were determined. Two hematology, two surgery, and two obstetrics/gynecology high-impact journals were similarly vetted.</p><p><strong>Results: </strong>The h-indexes of, and industry payments to, US male physician authors were greater than those of and to US female physician authors across all four vetted journal disciplines, with the male-to-female ratio of median dollar payments being greatest for rheumatology. Whereas payments to male US physician authors tended to be larger than those to female US physician authors at low h-indexes, payments to female US physician authors, especially for rheumatology, tended to match and surpass those to male US physician authors as the h-indexes rose.</p><p><strong>Conclusion: </strong>Significant differences exist in industry payments and h-indexes between male and female US physician authors of publications in high-impact journals, especially high-impact rheumatology journals. Sex-associated differences in industry payments can be attributed, at least in part, to sex-associated differences in author impact.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 8","pages":"e70078"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12381470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial Analysis.","authors":"Yael Klionsky, Karina D Torralba, Katie Obermeyer, Lissa Padnick-Silver, Gordon Lam, Brian LaMoreaux","doi":"10.1002/acr2.70080","DOIUrl":"10.1002/acr2.70080","url":null,"abstract":"<p><strong>Objective: </strong>Gout is a type of painful inflammatory arthritis that affects patient health and quality of life, making remission a crucial goal. The Gout Hyperuricemia and Crystal-Associated Disease Network (G-CAN) recently proposed a standard definition for gout remission. Using adapted criteria from de Lautour et al and recent G-CAN criteria, this post hoc analysis used existing data from the Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase (MIRROR) randomized controlled trial (NCT03994731) to determine potential gout remission rates in patients with pegloticase-induced intensive urate-lowering.</p><p><strong>Methods: </strong>Based on the adapted gout remission criteria from de Lautour et al, remission was defined as meeting all of the following six criteria: resolution of ≥1 tophus, serum urate (SU) level <6 mg/dL, no gout flares in the previous three months, pain score ≤1 (10-point scale), swollen joint count ≤1, and Physician Global Assessment of Gout score ≤1. An abbreviated three-criteria definition, modeled after the G-CAN definition, included gout flare, SU level, and tophus resolution.</p><p><strong>Results: </strong>A total of 145 patients received ≥1 dose of pegloticase (pegloticase with methotrexate, n = 96; pegloticase with placebo, n = 49), with 90 and 74 patients remaining on treatment through weeks 24 and 52, respectively. At weeks 24 and 52, 13.3% of patients (12 of 90) and 43.2% of patients (32 of 74) achieved gout remission using the six-criteria definition, and 36.7% (33 of 90) and 70.3% of patients (52 of 74) achieved remission using the three-criteria definition.</p><p><strong>Conclusion: </strong>Using the study full and simplified definitions, nearly half to three-quarters of patients who remained on pegloticase for 52 weeks achieved gout remission. This novel analysis provides evidence that remission is possible in many patients with uncontrolled gout within one year of intensive, sustained urate-lowering.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 8","pages":"e70080"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Images: Destructive sarcoid arthropathy of the small joints.","authors":"Ibiyemi Oke, Mary Stone, Petar Lenert","doi":"10.1002/acr2.70087","DOIUrl":"10.1002/acr2.70087","url":null,"abstract":"","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 7","pages":"e70087"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Knee Pain Frequency and Severity with Quadriceps Strength but Not Rate of Decline Over Four Years.","authors":"David A Sherman, Tuhina Neogi, Samantha Hornsby, David Felson, Michaell Lavalley, Joshua J Stefanik","doi":"10.1002/acr2.70067","DOIUrl":"10.1002/acr2.70067","url":null,"abstract":"<p><strong>Objective: </strong>Quadriceps weakness increases the risk of knee osteoarthritis (OA) and functional decline. Understanding how quadriceps strength changes over time is crucial for managing knee OA. Knee pain and effusion may influence strength over time through inhibition of motor pathways, but this remains a critical knowledge gap. We aimed to determine quadriceps strength trajectories and the association of knee pain and effusion among individuals with or at risk of knee OA.</p><p><strong>Methods: </strong>We used baseline, two-year, and four-year quadriceps strength data from the Osteoarthritis Initiative to identify quadriceps strength trajectory groups using discrete mixture model clustering. Pain and effusion were assessed at baseline. We determined the relation of pain and effusion to trajectory groups using multinomial logistic regression, adjusted for demographics and radiographic OA.</p><p><strong>Results: </strong>From 2,527 participants, three strength trajectories were identified for both sexes (\"weak,\" \"average,\" and \"strong\"), all with a linear decline in strength over four years. In women, individuals with frequent knee pain had higher odds of being in the weakest trajectory group compared to the average (odds ratio [OR] 0.54 [95% confidence interval (CI) 0.43-0.68]) and strong trajectories (OR 0.46 [95% CI 0.32-0.65]). Worse pain severity increased the odds of weakest trajectory group compared to the average (OR 0.89 [95% CI 0.85-0.93]) and strong strength trajectories (OR 0.86 [95% CI 0.80-0.92]). Effusion showed no association. Similar effects were present in men.</p><p><strong>Conclusion: </strong>Frequent knee pain and knee pain severity were associated with being in a lower quadriceps strength trajectory group, but the rate of strength decline over four years was similar across all groups, suggesting that pain may not influence the rate of decline.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 7","pages":"e70067"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-Blood RNA Sequencing Profiling of Patients With Rheumatoid Arthritis Treated With Tofacitinib.","authors":"Chiara Bellocchi, Ennio Giulio Favalli, Gabriella Maioli, Elena Agape, Marzia Rossato, Matteo Paini, Adriana Severino, Barbara Vigone, Martina Biggioggero, Elena Trombetta, Roberto Caporali, Lorenzo Beretta","doi":"10.1002/acr2.11761","DOIUrl":"10.1002/acr2.11761","url":null,"abstract":"<p><strong>Objective: </strong>Patients with rheumatoid arthritis (RA) often fail to respond to therapies, including JAK inhibitors (JAKi), and treatment allocation is made via a trial-and-error strategy. A comprehensive analysis of responses to JAKi, including tofacitinib, by RNA sequencing (RNAseq) would allow the discovery of transcriptomic markers with a two-fold meaning: (1) an improved knowledge about the mechanisms of response to treatment (inference modeling) and (2) the definition of features that may be useful in treatment optimization and assignment (predictive modeling).</p><p><strong>Methods: </strong>Thirty-three patients with active RA were treated with a tofacitinib dose of 5 mg twice a day for 24 weeks and evaluated for EULAR Disease Activity Score in 28 joints using the C-reactive protein level response. Whole-blood RNA was collected before and after treatment to perform RNAseq transcriptome analysis. Linear models were used to determine differentially expressed genes (DEGs) (1) at baseline according to clinical responses and (2) in the pre-post comparison after tofacitinib treatment and in relation to EULAR responses. The capability of DEGs to predict a successful treatment was tested via machine learning modeling after extensive internal validation.</p><p><strong>Results: </strong>Of 26 patients who completed the study (per-protocol analysis), 15 (57.7%) achieved good responses, and 7 (26.9%) and 4 (15.3%) had moderate and no responses, respectively. Overall, 273 baseline genes were significantly associated with the attainment of good responses, contributing to several pathways linked to the immune system or RA pathogenesis (eg, citrullination processes and the negative regulation of natural killer function). The expression of several molecules was reverted by tofacitinib when good responses were reached, including AKT3, GK5, KLF12, FCRL3, BIRC3, TSPOAP1, and P2RY10. Finally, we isolated 14 markers that singularly were capable of predicting the attainment of good responses, including, NKG2D, CD226, CLEC2D, and CD52.</p><p><strong>Conclusion: </strong>Whole-blood transcriptome analysis of patients with RA treated with tofacitinib identified genes whose expression may be relevant in prognostication and understanding the mechanisms of responses to therapy.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":" ","pages":"e11761"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies\".","authors":"","doi":"10.1002/acr2.70086","DOIUrl":"10.1002/acr2.70086","url":null,"abstract":"","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 7","pages":"e70086"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Disease Activity in Pediatric Chronic Nonbacterial Osteomyelitis: A Proposal for Composite Scoring, Including Inactivity Measures.","authors":"Christiane Reiser, Jens Klotsche, Anja Schnabel, Christine Hofmann, Nadine Groesch, Martina Niewerth, Kirsten Minden, Hermann Girschick","doi":"10.1002/acr2.70061","DOIUrl":"10.1002/acr2.70061","url":null,"abstract":"<p><strong>Objective: </strong>Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease with no validated criteria for assessing disease activity (DA), inactive disease, or remission. To date, DA assessment has relied on subjective judgments from patients, rheumatologists, and/or radiologists. Evaluations based on composite DA measures are emerging. The Pediatric CNO (PedCNO) response score documents relative DA changes during follow-up in analogy to the Pediatric American College of Rheumatology score for juvenile idiopathic arthritis. The international Childhood Arthritis and Rheumatology Research Alliance (CARRA) CNO initiative proposed a numeric composite DA score (CDAS) on the basis of the patient global assessment of DA (PAG), patient assessment of pain (PAP), and clinically active CNO lesions. We aim to propose different composite scores for assessment of DA, including physician assessment of DA and magnetic resonance imaging (MRI) findings; to evaluate the previously published CNO CDAS and the PedCNO response score using established registry data; and to suggest a PedCNO 90% improvement (PedCNO90) category.</p><p><strong>Methods: </strong>Newly diagnosed patients with CNO were enrolled between 2015 and 2020 and analyzed for clinical course and DA measures (physician global assessment of DA [PGDA]/PAG and pain scores) for up to 4 years of follow-up (YFU) in the National Pediatric Rheumatologic Database.</p><p><strong>Results: </strong>A total of 400 patients were enrolled. In single numeric scores only, clinical and MRI lesion scores reached significant changes (from baseline to 3 YFU: P = 0.003/P = 0.004). Composite scores, which include MRI DA scores consisting of one clinical patient-based assessment parameter (PAG/PAP of DA), the PGDA and MRI lesion count are less dependent on subjective measures and demonstrate more pronounced changes over time of supposed CNO DA compared with the CNO CDAS. A PedCNO90 response score gradually increased during follow-up, ultimately reaching a PedCNO90 in half of the remaining patients after 4 years.</p><p><strong>Conclusion: </strong>Composite scores, including MRI lesions and PGDA, seem to be promising tools for describing the activity of CNO and are proposed. The composition of DA scores seems essential for future studies.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 7","pages":"e70061"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Soluble Immune Checkpoint Molecules PD1 and 4-1BB With CTLA-4Ig Treatment Response in Early Rheumatoid Arthritis.","authors":"Tilia Selldén, Kristina Lend, Jon Lampa, Merete Lund Hetland, Mikkel Østergaard, Tillmann Uhlig, Dan Nordström, Kim Hørslev-Petersen, Björn Gudbjörnsson, Gerdur Gröndal, Inger Gjertsson, Ronald van Vollenhoven, Cristina Maglio, Kerstin Andersson, Anna-Karin Hultgård Ekwall, Anna-Carin Lundell, Anna Rudin","doi":"10.1002/acr2.70069","DOIUrl":"10.1002/acr2.70069","url":null,"abstract":"<p><strong>Objective: </strong>To investigate whether soluble immune checkpoint molecules in blood are associated with the treatment response to disease-modifying antirheumatic drugs in early rheumatoid arthritis (eRA).</p><p><strong>Methods: </strong>This study included 328 Swedish treatment-naïve patients with eRA from the Nordic Rheumatic Diseases Strategy Trials and Registries (NORD-STAR) study. Patients were randomized into four treatment groups: methotrexate (MTX) combined with CTLA-4Ig (n = 90), anti-tumor necrosis factor (n = 83), anti-interleukin-6 receptor (n = 76), or prednisolone (n = 79). The primary outcome was remission, defined by Clinical Disease Activity Index (CDAI) ≤2.8, assessed at 24 and 48 weeks. Plasma levels of soluble programmed cell death-1 (sPD1) and soluble 4-1BB (s4-1BB) were measured by enzyme-linked immunosorbent assay at baseline and at weeks 24 and 48 after treatment initiation.</p><p><strong>Results: </strong>High baseline levels of sPD1 and s4-1BB were both associated with CDAI remission at 24 weeks (odds ratio 1.31, 95% confidence interval [CI] 1.04-1.66 and odds ratio 1.50, 95% CI 1.07-2.11, respectively) in patients treated with CTLA-4Ig with MTX, but not in any other treatment groups. Furthermore, baseline levels of sPD1 or s4-1BB together with proportions of PD1⁺ T follicular helper (TFh) cells predicted treatment response to CTLA-4Ig with MTX after 48 weeks, achieving 90% and 100% positive predictive value, respectively.</p><p><strong>Conclusion: </strong>High plasma levels of sPD1 and s4-1BB are associated with good response to CTLA-4Ig with MTX therapy in patients with eRA. A combination of sPD1 or 4-1BB levels and the proportions of PD1⁺ TFh cells in blood at baseline has potential for predicting remission after CTLA-4Ig treatment.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 7","pages":"e70069"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Images: Magnetic resonance imaging changes of bone marrow edema in the hands in Raynaud phenomenon.","authors":"Patrick Mulkerrin, Michael Courtney, Finbar O'Shea","doi":"10.1002/acr2.70088","DOIUrl":"10.1002/acr2.70088","url":null,"abstract":"","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 7","pages":"e70088"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of miR-190a-5p and miR-26b-5p as Potential microRNA Biomarkers for Psoriatic Arthritis.","authors":"Omar F Cruz-Correa, Darshini Ganatra, Ameth N Garrido, Rohan Machhar, Starlee Lively, Mohit Kapoor, Dafna D Gladman","doi":"10.1002/acr2.70014","DOIUrl":"10.1002/acr2.70014","url":null,"abstract":"<p><strong>Objective: </strong>Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory arthritis that develops in 30% of patients with psoriasis, leading to increased morbidity and mortality and reduced quality of life. MicroRNAs (miRNAs) modulate gene expression and have been associated with the pathogenesis of immune-mediated disorders. We aimed to identify miRNAs that can be used as biomarkers for the development of PsA in patients with psoriasis.</p><p><strong>Methods: </strong>miRNA expression levels were assessed in serum samples from 28 patients with PsA, 35 patients with cutaneous psoriasis without arthritis (PsC), and 28 healthy controls through next-generation sequencing. Differential expression was assessed by linear modeling with empirical Bayes moderation corrected for sequencing batch, age, sex, and duration of psoriasis. For validation, we measured the expression of >191 genes predicted to be targeted by the dysregulated miRNAs using a custom NanoString probe panel in an independent cohort of 144 patients with PsA and 88 patients with PsC. The enrichment of specific pathways corresponding to the differentially expressed gene targets was examined using pathDIP.</p><p><strong>Results: </strong>In the discovery cohort, the miRNA miR-190a-5p was significantly down-regulated in patients with PsA compared to those with PsC (P< 0.05), and both miR-190a-5p and miR-26b-5p were down-regulated in patients with PsA versus healthy controls (P < 0.05). In the validation cohort, 26 gene targets of both of these miRNAs were differentially expressed. These genes were enriched in signaling pathways associated with bone formation and regeneration: Wnt and transforming growth factor β.</p><p><strong>Conclusion: </strong>Serum expression levels of miR-190a-5p and miR-26b-5p can potentially serve as biomarkers for PsA development.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 7","pages":"e70014"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}